Among the small number of BPC-157 reports the FDA has received, one involved a product labeled research purposes only: the patient developed skin and gum discoloration that resolved when she stopped and returned when she restarted it
Acylation with a fatty acid side chain enables albumin binding and a half-life of approximately 57 days, supporting once-weekly administration
This product is intended strictly for in vitro research ONLY and is NOT approved for human use, clinical application, or human consumption
Maintenance phase: After noticeable improvement, some protocols suggest reducing to 2-6 mg per month , adjusted according to clinical evaluation
They were given in their homecages ad libitum access to water and either a standard chow diet (PicoLab Rodent Diet 20, St
A Multi-Faceted Ally in Recovery For those living with chronic Lyme disease, where pain, fatigue, and immune chaos dominate daily life, BPC-157 represents a multi-layered therapeutic option